SSY Group Wins China Approval for New Oncology Injection

SSY Group ( (HK:2005) ) just unveiled an announcement.

SSY Group has received approval from China’s National Medical Products Administration to produce and register its Calcium Levofolinate for Injection 25mg, classified as a type 3 chemical drug that has passed consistency evaluation. The injectable is mainly indicated for use in combination with 5-fluorouracil in treating gastric and colorectal cancers, marking a further expansion of the group’s oncology portfolio and strengthening its position in China’s hospital drug market.

The voluntary announcement signals progress in SSY Group’s product pipeline and may enhance its competitive edge in the high-demand oncology segment. While the company has not disclosed commercial timelines, the regulatory clearance supports its strategy of broadening approved injectable therapies and could improve its long-term growth prospects in the Chinese pharmaceutical sector.

The most recent analyst rating on (HK:2005) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

More about SSY Group

SSY Group Limited is a China-focused pharmaceutical company engaged in the research, development, production, and sale of drug products. The group concentrates on injectable formulations and other hospital-use medicines, serving therapeutic areas such as oncology and critical care within the mainland Chinese healthcare market.

Average Trading Volume: 6,113,100

Technical Sentiment Signal: Sell

Current Market Cap: HK$7.26B

Find detailed analytics on 2005 stock on TipRanks’ Stock Analysis page.